Medigene AG
Medigene AG, a pioneering biotechnology company headquartered in Germany, focuses on the development of innovative immunotherapies for cancer treatment. Founded in 1997, Medigene has established itself as a leader in the field, particularly in the areas of T cell immunotherapy and personalised medicine. With a strong operational presence in Europe and North America, the company is renowned for its unique core products, including its proprietary T cell receptor (TCR) technology, which enables the targeting of specific cancer cells. Medigene's commitment to advancing cancer therapies has led to significant milestones, including successful clinical trials and strategic partnerships that enhance its market position. As a result, Medigene AG continues to be at the forefront of the biopharmaceutical industry, driving innovation in cancer treatment.
DitchCarbon Score
How does Medigene AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medigene AG's score of 30 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medigene AG's reported carbon emissions
In 2023, Medigene AG reported total carbon emissions of approximately 458,590 kg CO2e, all of which fall under Scope 1 emissions. There were no reported emissions for Scope 2 or Scope 3, indicating that the company has not yet addressed indirect emissions from energy consumption or value chain activities. Comparatively, in 2022, Medigene AG's Scope 1 emissions were slightly higher at about 492,850 kg CO2e. This reflects a reduction of approximately 34,260 kg CO2e year-on-year, showcasing a positive trend in their emissions management. Despite these reductions, Medigene AG has not established any formal reduction targets or commitments, such as those aligned with the Science Based Targets initiative (SBTi). The absence of specific climate pledges or initiatives suggests that while the company is making strides in reducing its direct emissions, there is still significant room for improvement in its overall climate strategy. Medigene AG's emissions data is not cascaded from any parent organization, indicating that the reported figures are solely from their own operations. As the company continues to evolve, it may benefit from setting clear climate commitments to enhance its sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 492,850 | 000,000 |
| Scope 2 | - | - |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medigene AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
